Most companies are, by definition, mediocre. Some are good. Fewer still are great. And a tiny minority are truly exceptional. These are the ones I want to own. I’m looking to invest in durable, adaptable and – above all – resilient businesses; those selling critical goods and services, with high levels of recurring income from loyal customers. I believe the three companies below pass these tests with flying colours.
Experian (LSE: EXPN) owns the world’s largest credit bureau. It aggregates credit data from lenders, then sells it back to them. Without this data, banks would not be able to lend and the world economy would grind to a halt. Experian has successfully expanded into new applications, using its data in more ways to solve more problems for more customers in more industries.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Danaher Corporation: a top "picks and shovels" play
In the California gold rush, it wasn’t the gold miners who made the most money. It was the companies supplying the picks and shovels. Danaher Corporation (NYSE: DHR) has positioned itself as the picks-and-shovels provider to the medical-science industry.
The company provides diagnostic tests, life-sciences instruments and technologies for the development, manufacture and delivery of biological drugs. The diversity of its product portfolio, leadership positions in highly regulated markets and global scale add up to a resilient business that is difficult to compete with.
That said, it hasn’t been plain sailing in recent years. The pandemic saw a boom in spending from pharmaceutical and biotechnology companies. When that trend reversed and these companies cut back on inventories, Danaher’s revenue and profit took a hit. The good news is that demand for biological therapies is still growing rapidly. And with most of Danaher’s customers having worked through excess inventories and returned to normal ordering patterns, the stage could be set for a return to growth.
I highlighted Roper Technologies (Nasdaq: ROP) as one of my favourite shares last year for MoneyWeek. I have chosen to do so again because I believe the firm is at an interesting juncture. Roper owns 28 high-quality software and technology businesses, generating excellent margins and cash flow, and has a strong record of acquisitions and disposals.
But 2024 wasn’t a vintage year. Tough market conditions for a few of its business subsidiaries held back organic growth. Those headwinds now appear to be easing and beneath the surface it is making excellent strides. Having disposed of its more cyclical businesses, Roper is now attempting to get the most out of its existing operations. This includes a sharper focus on strategy, talent and new product development, such as incorporating generative AI into its software solutions.
Roper’s acquisition strategy is also evolving. There is a greater focus on “bolt-on” deals that can be assimilated into existing firms, and buying businesses at a slightly earlier stage of their development, with stronger growth prospects. In short, I think Roper’s mid- to long-term growth prospects are improving. This could be the year that progress becomes more evident.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
How to achieve a secure retirement, as more retirees admit to struggling with debtTwenty-six percent of retirees now have unsecured debt – a sharp rise compared to two years ago – with many underestimating how much a typical retirement costs
-
The key October self-assessment tax return deadlines to remember so you can avoid a shock billThere are two important dates for self-assessment taxpayers to remember in October
-
Small UK industrial stocks are hidden gemsOpinion Ed Wielechowski of the Odyssean Investment Trust highlights three of his favourite British small-cap industrial stocks
-
Aurora Innovation is running on empty – is it overvalued?Aurora Innovation, a maker of self-driving trucks, may have promised far more than it can deliver
-
'Ride the recovery in emerging markets': Gustavo Medeiros of Ashmore Group tells MoneyWeekInterview What's the outlook for emerging markets? Gustavo Medeiros, head of research at Ashmore Group, gives his analysis and reviews progress in developing economies
-
What is the Enterprise Investment Scheme and should you have one?The Enterprise Investment Scheme is tax-efficient and potentially lucrative. Taking a chance on the scheme could trim your family’s IHT bill, says David Prosser
-
The alcohol industry is suffering as consumers sober up – is it still worth investing in the sector?Changing consumer tastes are rocking the alcohol industry, but the best players are adapting their strategies. Buy them while their shares are still cheap
-
A strange calm in creditCorporate bond markets remain remarkably relaxed, with yields that offer little compensation for risks
-
'The City's big bet on green finance fails to pay out'Opinion Insurers and banks are backing away from “green finance”, and there is not much sign of the green boom we were promised. That’s a problem for the City
-
Six top investment trusts for smaller stocksLiquidity constraints mean investment trusts are best placed to seize the juiciest opportunities
